Savara Inc (NASDAQ:SVRA - Get Free Report) Director Joseph S. Mccracken bought 10,000 shares of the company's stock in a transaction on Thursday, May 29th. The shares were acquired at an average cost of $2.08 per share, for a total transaction of $20,800.00. Following the completion of the acquisition, the director now directly owns 260,837 shares of the company's stock, valued at $542,540.96. This trade represents a 3.99% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Savara Stock Performance
SVRA remained flat at $2.40 on Tuesday. 1,097,767 shares of the company were exchanged, compared to its average volume of 1,425,688. The firm has a 50 day moving average of $2.91 and a two-hundred day moving average of $2.94. The stock has a market cap of $414.81 million, a P/E ratio of -5.58 and a beta of 0.44. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. Savara Inc has a 12-month low of $1.89 and a 12-month high of $5.11.
Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.12). Research analysts predict that Savara Inc will post -0.45 EPS for the current year.
Analysts Set New Price Targets
Several research firms have recently commented on SVRA. Guggenheim restated a "buy" rating and set a $8.00 price target (down previously from $9.00) on shares of Savara in a research report on Wednesday, May 28th. HC Wainwright lowered shares of Savara from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $6.00 to $2.00 in a research report on Thursday, May 29th. Evercore ISI lowered their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research report on Wednesday, May 28th. Finally, Wells Fargo & Company lowered their price target on shares of Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Wednesday, May 28th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $7.17.
Check Out Our Latest Report on Savara
Hedge Funds Weigh In On Savara
Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Savara by 4.6% in the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock valued at $25,512,000 after buying an additional 365,959 shares in the last quarter. SG Americas Securities LLC grew its position in Savara by 14.0% in the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company's stock valued at $158,000 after buying an additional 6,330 shares in the last quarter. Geode Capital Management LLC grew its position in Savara by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company's stock valued at $8,549,000 after buying an additional 57,187 shares in the last quarter. Deutsche Bank AG grew its position in Savara by 6.1% in the 4th quarter. Deutsche Bank AG now owns 927,595 shares of the company's stock valued at $2,848,000 after buying an additional 53,054 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its position in Savara by 314.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company's stock valued at $217,000 after buying an additional 53,547 shares in the last quarter. Institutional investors own 87.93% of the company's stock.
Savara Company Profile
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Further Reading
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
